Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

EPOCH-O regimen

An immune-chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, doxorubicin (hydroxydaunorubicin) and ofatumumab, which may be used for the treatment of various aggressive non-Hodgkin lymphomas.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	DA EPOCH-O dose-adjusted EPOCH-ofatumumab dose-adjusted etoposide-prednisone-vincristine-cyclophosphamide-ofatumumab dose-adjusted etoposide/vincristine/doxorubicin/cyclophosphamide/prednisone plus ofatumumab regimen EPOCH plus Arzerra EPOCH plus ofatumumab etoposide-prednisone-Oncovin-cyclophosphamide-hydroxydaunorubicin-ofatumumab regimen O-EPOCH O-EPOCH regimen
Abbreviation:	EPOCH-O

EPOCH-O regimen

Search NCI's Drug Dictionary